The new autoinjector option increases convenience, enhances individual patient experience and expands administration options
Celltrion, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma, a biosimilar to Stelara (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD).
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 15 December 2025
The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion.
“The new SteQeyma autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatment options that support ease of use and improve adherence,” said Taehun Ha, Senior Vice President and Head of Europe Division at Celltrion. “This marks an important milestone in strengthening Celltrion’s immunology portfolio and reaffirms our pioneering leadership in the global biosimilar sector, as we remain committed to reducing the healthcare burden, improving patients’ quality of life, and enhancing the overall patient experience.”
Health Technology Insights: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer
With this new addition, SteQeyma broadens the administration option, giving patients and physicians access to a complete range of administration options. The new SteQeyma autoinjector enables patients and caregivers to administer the medicine via a simple two-step process. The device includes two clear visual and audible indicators – a viewing window and audible clicks to support patients easily identify the injection status, which guide patients with successful administration. SteQeyma autoinjector is citrate-free with special thin-wall needle technology to help reduce injection pain. It also offers a 4-year shelf life and can be re-refrigerated, helping reduce product disposal.
SteQeyma is currently licensed in more than 40 countries worldwide, including the US, Japan and EU countries. Alongside Remsima SC, a subcutaneous formulation of infliximab approved in the EU, SteQeyma joins Celltrion’s distinguished portfolio that includes Remsima (biosimilar infliximab), Truxima (biosimilar rituximab), Herzuma (biosimilar trastuzumab), Yuflyma (biosimilar adalimumab), Vegzelma (biosimilar bevacizumab), Omlyclo (biosimilar omalizumab), Avtozma (tocilizumab biosimilar), Osenvelt/Stoboclo (biosimilar denosumab), Eydenzelt and Remsima (biosimilar infliximab) IV liquid formulation.
Health Technology Insights: Infinitus Launches Next-Generation Clinical AI Agents
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
